> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Deep Track Capital Reports 8.61% Passive Stake In Alector
- URL: https://www.bullished.co/deep-track-capital-reports-8-61-passive-stake-in-alector-91533e69/
- Published: 2026-10-23T20:11:08.000Z
- Updated: 2026-11-05T20:22:13.000Z
- Description: The Greenwich-based adviser and an affiliated fund hold 12,772,152 Alector shares, with no aim of influencing control.
- Author: Matteo Parrino
- Tags: SEC Filings, ALEC, Industry: Healthcare

Deep Track Capital, a Greenwich, Connecticut investment adviser, reported a passive [8.61% stake](https://www.sec.gov/Archives/edgar/data/0001856083/000117266126004680/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Alector](https://www.bullished.co/tag/alec/), covering 12,772,152 common shares, in a passive ownership filing made Friday. The group certified it holds the shares without any purpose of changing or influencing control of the biotech.

## Three filers, one block of shares

The filing names three reporting persons: Deep Track Capital, LP, an investment adviser; Deep Track Biotechnology Master Fund, Ltd., a Cayman Islands company; and David Kroin. Each reports the same [12,772,152 shares](https://www.sec.gov/Archives/edgar/data/0001856083/000117266126004680/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) and the same 8.61% of the class.

None of the three holds sole voting power. Voting power over all the shares is shared among them. The filing identifies Deep Track Capital as the entity through which Kroin may be considered a control person.

The 8.61% is the cover-page percentage under Rule 13d-3, which counts shares a holder could acquire within 60 days in both the holding and the share base. The filing lists October 16 as the event date, and the group certified the shares were not acquired and are not held to affect control of Alector.

## A biotech with no products yet

Alector, based in South San Francisco, is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It has no products on the market, according to its annual report for 2025.

Its lead candidate, nivisnebart, is an antibody designed to raise levels of the protein progranulin in the brain. It is being developed with GSK and is in a mid-stage trial in early Alzheimer's disease that enrolled about 282 patients. Under the GSK agreement, Alector received $700 million in upfront payments and may receive milestone payments.

## Where the stock stands

Alector shares closed at $1.83 at Friday's close, flat on the session, for a market value of $204 million.

The certification matters for what the stake is not: a passive filing, with no stated intent to seek influence over Alector's control.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Deep Track Capital, LP re: Alector, Inc. (ALEC)](https://www.sec.gov/Archives/edgar/data/0001856083/000117266126004680/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Alector

- [RA Capital Takes 5.1% Of Alector, Holding 7.5 Million Shares After Stock Offering](https://www.bullished.co/ra-capital-takes-5-1-of-alector-holding-7-5-million-shares-after-stock-offering-34840dda/)
- [Alector Prices 36.6 Million Shares At $2.05, Adding 24.7% To Its Share Count](https://www.bullished.co/alector-prices-36-6-million-shares-at-2-05-adding-24-7-to-its-share-count-c18352d8/)
- [Alector Prices Stock Sale At $2.05 A Share, Aiming For $75.03 Million In Gross Proceeds](https://www.bullished.co/alector-prices-stock-sale-at-2-05-a-share-aiming-for-75-03-million-in-gross-proceeds-8f6be697/)

[All Alector (ALEC) coverage →](https://www.bullished.co/tag/alec/)